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Abstract
Aims To report on the relationships between age at diagnosis of diabetes, time from registration with the screening
programme to first diabetic eye screening and severity of diabetic retinopathy.
Methods Data were extracted from four English screening programmes and from the Scottish, Welsh and Northern
Irish programmes. Time from diagnosis of diabetes to first screening and age at diagnosis were calculated.
Results Time from registration with the screening programme to first screening episode is strongly related to age at
registration. Within 18 months of registration 89% of 3958 young people under 18 years of age and 81% of 391 293
people over 35 years of age were seen. In 19 058 people between 18 and 34 years of age, 80% coverage was not reached
until 2 years and 9 months. The time from diagnosis of diabetes to first screening is positively associated with severity of
disease (P < 0.0001).
Conclusions This report is the first that to demonstrate that those in the 18–34 year age group are least likely to attend
promptly for screening after registration with a higher risk of referable diabetic retinopathy being present at the time of
first screen. Date of diagnosis should be recorded and prodigious efforts made to screen all people promptly after
diagnosis. Screening programmes should collect data on those who have not attended within one year of registration.
Diabet. Med. 00: 000–000 (2015)
Introduction
Diabetic retinopathy is a microvascular consequence of
diabetes, which in advanced stages leads to vision loss and
blindness, with significant impact on health status and
quality of life for people with diabetes.
Annual screening for diabetic retinopathy is recommended
in England, Scotland, Wales and Northern Ireland (the Four
Nations) for all those with diabetes aged 12 and above. The
decision to screen annually was a pragmatic policy decision
taken when national screening programmes were introduced
in the Four Nations of the UK in 2002–2003. When the
English screening programme was established in 2003 it was
estimated that there were ~ 1.4 million people with diabetes
in England. The number in 2013 is estimated to be
2.6 million, with the number in the UK as a whole having
exceeded 3 million in 2013 [1], driven by lifestyle factors and
the ageing population.
The Four Nations Diabetic Retinopathy Screening Inter-
vals Project was established by the National Screening
Committee in May 2012 to determine whether evidence
supports the introduction of individualized screening inter-
vals based on estimated risk of developing referable diabetic
retinopathy (defined below) which is the threshold for
referral to a hospital eye service. Data sets were obtained
from Scotland, Wales, Northern Ireland and from four
English screening programmes to examine the performance
of an algorithm to estimate risk [2] and a recent report on
this has been published [3].
A recent report in one English screening programme [4]
highlighted the elevated rate of detection of referable diabetic
retinopathy in those who were not screened promptly after
diagnosis of Type 2 diabetes. The analyses reported here
were designed to examine the relationship between time from
diagnosis of diabetes and diabetic retinopathy level at first
screening episode, and time from registration to screening by
age group, in a very large data set.
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The current quality standard in the Four Nations pro-
grammes is the overall percentage uptake of the screening
programme annually. There is no differentiation of those
who have never been screened before or who have not
attended for several years.
Patients and methods
Data for people referred to the eye screening programme and
grading results at first screen were extracted from the
screening programme databases. The retrospective analysis
of anonymized data did not require ethical approval.
Caldicott Guardian approval was given for use of the data
in each of the screening programmes who contributed data.
Data for the Four Nations study were taken from seven
diabetic retinopathy screening programmes: whole nation
programmes in Wales, Scotland and Northern Ireland and
four local English programmes (Brighton, Derbyshire, Leeds
and Staffordshire). The inclusion criteria for this Four Nations
data set have been reported in a previous publication [3]. The
four English programmes were chosen to cover urban and rural
areas, high and low levels of socio-economic deprivation and to
include programmes with sizeable ethnic minority populations.
One programme was from the North of England, two were
from the Midlands and one from the South of England. We
included programmes that were assessed as not having any
problems with their grading at their most recent External
Quality Assurance visit, had a population screening size of
> 20 000 people with diabetes, and were willing to participate.
We consider these programmes to encompass much of the
heterogeneity seen in the English screening programme. For the
present study, some programmes were excluded because of
incomplete time data, as follows.
Recording the date of diagnosis of diabetes is not a
mandated item in the English NHS diabetic eye screening
programme data set. Hence, in the analysis of retinopathy
levels vs. time from diagnosis to screening, data were
included from the Scotland, Wales, Northern Ireland and
two English programmes. One of the English programmes
not included had no diagnosis date and the other had date of
diagnosis for only 8% of the participants.
In the analysis, time to screening from registration, data
were included from Scotland and three English programmes.
Data were not included from Wales because they registered
participants only when they were first screened, from the
Northern Irish data set because it had had been running for a
far shorter time than the other programmes, and from one
English programme because the date when the patient was
registered on the central collated list was not recorded in the
database. National Institute for Health and Care Excellence
(NICE) Type 1 and Type 2 guidelines [5,6] and the SIGN
guideline [7] on diabetes both recommend that eye screening
should be arranged at or around the time of diagnosis of
diabetes from 12 years onwards.
In the English NHS Diabetic Eye Screening Programme all
images are allocated a retinopathy (R) grade and a maculopa-
thy (M) grade on the basis of the absence, presence and
severity of features of diabetic retinopathy found during
quality assured grading of the retinal images. The criteria used
for grading and allocation of R andM levels are those required
by the English NHS Diabetic Eye Screening Programme [8]
and the relationship to the Early Treatment Diabetic Retinopa-
thy Study (ETDRS) severity scale [9,10] are shown in Table 1.
Referable diabetic retinopathy was defined in the English
programmes by the presence of any of R2 (moderate to severe
non-proliferative diabetic retinopathy), R3 (proliferative dia-
betic retinopathy) or M1 (maculopathy) in at least one eye and
the equivalent levels were identified in the Scottish screening
programme. Patients with unassessable images of either or
both eyes were excluded from these analyses.
In the analysis of retinopathy levels vs. time from diagnosis
to screening, data were analysed using Mantel–Haenszel chi-
square tests. The retinopathy levels analysed are defined in
Table 1 by the levels no diabetic retinopathy, mild non-
proliferative diabetic retinopathy in one eye, mild non-
proliferative diabetic retinopathy in both eyes, referable
diabetic retinopathy (moderate non-proliferative diabetic
retinopathy or maculopathy), fast track referable diabetic
retinopathy (proliferative diabetic retinopathy) and the
number and percentage of these grades and ungradable
image sets is shown in Table 2. Logistic regression was used
to analyse the effects of duration of diabetes and age at time
of screening, type of diabetes and gender (Table 3).
Time from registration on the programme’s central
collated list to date of screen was analysed using Kaplan–
Meier estimates with follow-up censored on 1 January 2012
stratified by age at registration. Figure 1 shows the time to
screening by age group overall, and Fig. 2 shows the time to
screening by age group within each programme. Further
analysis was carried out of time to screening using paramet-
ric survival models to look at the effects of age and gender.
Results
Over all seven programmes there were 689 025 people on
the registers. Of these, 54.9% were men, 43.1% women and
2.0% had no gender recorded. Of these, 512 944 had a date
of diagnosis of diabetes (74.4%); by programme the respec-
tive proportions were 0%, 8%, 58%, 77%, 79%, 99.6% and
What’s new?
• People in the 18–34 year age group are more likely to
have a longer time interval between registration with
the screening programme and attendance for screening.
• People with a longer time interval between registration
and attendance for screening are at a greater risk of
referable diabetic retinopathy being present at the time
of first screen.
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99.8%. Type of diabetes was recorded for 620 281, of these
9.4% had Type 1 diabetes and 90.6% had Type 2 diabetes.
Median age of diagnosis of Type 1 diabetes was 22 years
[interquartile range (IQR) 12–34], and for Type 2 diabetes
was 59 years (IQR 50–68). Of those who were screened for
the first time in 2011, date of diagnosis of diabetes was
available for 38 710 people from five programmes (pro-
grammes 1, 3, 4, 5 and 6). Of those with a type of diabetes
recorded, the proportion of people with any retinopathy and
with referable and ‘fast track’ referable diabetic retinopathy
(proliferative diabetic retinopathy) increased with time from
diagnosis to screening. Between those diagnosed in 2010 or
2011 and those diagnosed before 1990 the proportion with
any diabetic retinopathy increased from 18% to 67%, and
the proportion with ‘fast track’ referable diabetic retinopathy
increased from 0.1% to 8.7% (Table 2) (chi-squared for
trend P < 0.0001). Those diagnosed with diabetes before
1990 and first screened in 2010 or 2011 were 19 [95%
confidence interval (CI) 16 to 21] times more likely to have
referable diabetic retinopathy than those diagnosed in 2010
or 2011 and 69 (95% CI 47 to 101) times more likely to
have ‘fast track’ referable diabetic retinopathy. Figure 3
shows the data for each of the five screening programmes.
Logistic regression analyses were carried out on 27 090
people, 1183 of whom had referable retinopathy, and of
these 235 required urgent referral to ophthalmology. The
explanatory variables were date of diagnosis, gender, date of
registration, age at screening and type of diabetes. After
adjustment for age at screening, type of diabetes and gender,
the duration of diabetes and time from registration to
screening were each highly significant predictors of both
referable retinopathy and urgent referral (Table 3).
For the analysis of ‘age vs. time from registration to date of
first screening’, data were available for 3958 people aged 12–
17 years, 19 058 aged 18–34 years, 15 5496 aged 35–
59 years and 215 797 aged 60 years and above. Figure 1
demonstrates that the attendance soon after screening was
good in the 12–17-year age group and in those aged 35 and
above. Those least likely to attend for screening in the first
3 years after registration were those aged 18–34. In this age
group it was not until 2 years and 9 months after registration
that 80% of the people had been screened, this proportion
having been reached in all other age groups 18 months after
registration. At 2 years, one in seven of those aged below 18
or 35 or older have not attended for screening, but in the 18–
34 year age group the proportion was one in four. There was
heterogeneity between programmes in the time from regis-
tration to being screened for the first time as described in the
methods section. For those programmes that were included,
the proportions screened by 12 months ranged from 63% to
85% and at 36 months from 81% to 91%. In the 12–17-year
age group, 9.3% (95% CI 8.4 to 10.2) failed to attend for
screening over a 3-year period since diagnosis of diabetes,
compared with 18.3% (95% CI 17.8 to 18.7) in the 18–34
age group, 10.2% (95% CI 10.0 to 10.3) in the 35–59 ageTa
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group and 11.6% (95% CI 11.5 to 11.8) in the 60 and above
age group. Figure 2 shows a comparison of uptake between
screening programmes in different age groups.
The youngest age group (12–17 at registration) were
slower to attend for screening in the first 6 months than
those aged 35 and older, but the rate at which they attended
for screening did not attenuate in the same way as older
groups, so by 3 years this group were most likely to have
been screened. Cox proportional hazards models were not
appropriate because the hazards were not proportional.
Using a Weibull model, age group and gender were signif-
icantly associated with time to first screen (P < 0.0001 for
both classification variables). Using age 60 and above as a
reference group the parameter estimates for the 12–17, 18–
34 and 35–59 age groups, respectively, were 0.24 (95% CI
0.18 to 0.30), 0.71 (0.67 to 0.75) and 0.20 (0.18 to 0.21).
After adjustment for age, men were more likely to be
screened [parameter estimate –0.06 (–0.07 to –0.04)].
Discussion
Previous evidence demonstrates a strong positive association
between incidence of diabetic retinopathy and duration of
diabetes [11,12]. People on the screening register are invited
for screening within 3 months of registration and then
annually. If they fail to attend they are given two further
appointments and then recalled after 1 year in Scotland and
in England. However, they may choose not to take up the
invitation or may delay for two or more years before doing
so. For people who have moved between screening pro-
grammes the date of diagnosis will not be the date when the
patient is registered. However, as it is not currently possible
to share data and images between screening programmes it is
important that each programme has digital images soon after
the patient is registered in order to have a ‘baseline’ grading,
whether or not they are newly diagnosed.
Factors that are known to affect attendance are:
 patient age – young adult people had a higher propensity for
non-attendance at diabetic retinopathy screening [13,14];
 socio-economic deprivation [13,15];
 type of diabetes – attendance rates at diabetic retinopathy
screening lower in people with Type 1 diabetes [14];
 poor glycaemic control, hypertension and smoking [13];
and
 primary care practice and screening-team-related factors
[16].
Table 2 Results of first screening by date of diagnosis of diabetes, at first screening in 2011, all programmes combined
Year of
diagnosis
of diabetes
Total
image
sets
No retinopathy
Mild non-
proliferative
retinopathy in
one eye
Mild non-
proliferative
retinopathy in
both eyes
Referable
retinopathy
(not fast-
track)*
Fast track
referable
retinopathy* Ungradable†
n
% of
graded
image sets n
% of
graded
image
sets n
% of
graded
image
sets n
% of
graded
image
sets n
% of
graded
image
sets n
% of
all
image
sets
1989 and earlier 1,462 443 33.0 176 13.1 362 27.0 244 18.2 116 8.7 121 8.3
1990–1999 2,936 1,453 52.6 381 13.8 507 18.4 323 11.7 99 3.6 173 5.9
2000–2004 3,923 2,574 68.5 527 14.0 389 10.4 210 5.6 56 1.5 167 4.3
2005–2009 3,063 4,504 76.7 802 13.7 379 6.5 157 2.7 27 0.5 212 3.5
2010–2011 27,326 21,508 82.0 3,244 12.4 1,108 4.2 344 1.3 33 0.1 1,089 4.0
*Chi-squared for trend in the level of referable retinopathy (both fast track and not fast track) P < 0.0001.
†Chi-squared for trend in the proportion of ungradable image sets P < 0.0001.
Table 3 Patient characteristics associated with referable retinopathy
and urgent referral: logistic regression models including 27 090 people
with diabetes
Referable
retinopathy
Urgent referral
to ophthalmology
Odds ratio
and 95% CI
Odds ratio and
95% CI
Duration of diabetes
Up to 5 years
(reference)
1 1
5–9 years 3.5 (2.8–4.5) 4.5 (2.5–8.1)
10–19 years 10.7 (8.6–13.2) 17 (10–28)
20 years or more 15.8 (12.3–20.4) 33 (20–54)
Time from registration to first screen
Up to 2 months 1 1
2–11 months 1.2 (0.9–1.4) 1.5 (0.9–2.6)
12–35 months 1.9 (1.4–2.5) 2.8 (1.4–5.4)
36 months or more 2.9 (2.3–3.6) 4.3 (2.6–7.1)
Diabetes type
Type 1 1
Type 2 0.72 (0.58–0.90)
Age group
18–34 years
(reference)
1 1
35–59 1.4 (1.1–1.9) 1.1 (0.7–1.7)
60 and above 1.1 (0.8–1.5) 0.6 (0.4–1.0)
Gender
Male 1
Female 0.82 (0.72–0.93)
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The major concern is that there is an association between
non-attendance at screening, poor control of diabetes [17]
and blindness registration [18]. One missed attendance at a
retinal screening appointment is associated with a threefold
increase in needing laser photocoagulation subsequently
[13].
This report is the first that has demonstrated that those in
the 18–34-year age group aremore likely to have a longer time
interval between registration and attendance for screening
and a consequent greater risk of referable diabetic retinopathy
being present at the time of first screen. This is most likely to
be due to the known propensity of the 18–34-year age group
for non-attendance [17] and the likelihood that younger
people are more likely to have Type 1 diabetes. It is important
that people in these groups are screened because, in addition
to the significant quality of life implications, there are wider
economic consequences such as lost productivity. This report
also quantifies the increase in risk of referable and of
proliferative retinopathy seen in those who are not screened
promptly after registration, independently of the risk due to
duration of diabetes. Risk of proliferative retinopathy is four
times higher in those in whom screening is delayed 3 years or
more, suggesting that this group are different from those who
attend promptly. Further work could be undertaken with this
FIGURE 1 Kaplan–Meier curves of proportion screened since
registration, by age at registration.
FIGURE 2 Comparison of uptake between screening programmes in different age groups.
6
ª 2015 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
DIABETICMedicine Screening attendance and diabetic retinopathy level by age group  P. H. Scanlon et al.
group to understand reasons for delay and changes to
screening programmes that might reduce this,
This study from a large data set supports the suggestion
that screening programmes should collect data on those who
attend and on those who have not attended over a 1-, 2-, 3-,
4- and 5-year period. In addition to date of registration, the
date of diagnosis of diabetes should be routinely recorded.
Without these data it is impossible to identify the cohort of
people at high risk who have never attended for diabetic
retinopathy screening.
Screening programmes have different modalities of deliv-
ery and some differences of demographic characteristics of
their population. Supplementary information from this data
set (Fig. 2) demonstrates that some screening programmes
are better than others at getting young people in to be
screened. Protocols from screening programmes with higher
attendance could be used to improve attendance in those
with lower attendance.
The evidence from this study will also be helpful for those
planning new screening programmes.
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